Bristol Myers Squibb (BMY) Intangibles (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Intangibles for 18 consecutive years, with $17.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Intangibles fell 18.67% year-over-year to $17.4 billion in Q2 2026; TTM through Jun 2026 was $17.4 billion, a 18.67% decrease from a year earlier, with the FY2025 full-year figure at $19.1 billion, down 18.04% from the prior year.
• Intangibles was $17.4 billion for Q2 2026 at Bristol Myers Squibb, down from $18.2 billion in the prior quarter.
• Over five years, Intangibles peaked at $40.1 billion in Q1 2022 and troughed at $17.4 billion in Q2 2026.
• A 5-year average of $28.0 billion and a median of $28.0 billion in 2023 frame the typical range for Intangibles.
• Across the five-year window, Intangibles fell 2.41% in 2024 and sank 31.36% in 2025, its largest moves.
• Over 5 years, Intangibles stood at $35.9 billion in 2022, then fell by 24.5% to $27.1 billion in 2023, then slipped by 13.91% to $23.3 billion in 2024, then slipped by 18.04% to $19.1 billion in 2025, then slipped by 8.98% to $17.4 billion in 2026.
• The last three Intangibles figures came in at $17.4 billion (Q2 2026), $18.2 billion (Q1 2026), and $19.1 billion (Q4 2025), per Business Quant data.